We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

78 hedge funds and large institutions have $210M invested in Arcus Biosciences in 2019 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

533% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 3

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

22% more funds holding

Funds holding: 64 → 78 (+14)

1.44% more ownership

Funds ownership: 57.92% → 59.37% (+1.4%)

35% less capital invested

Capital invested by funds: $322M → $210M (-$112M)

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

Holders
78
Holders Change
+14
Holders Change %
+21.88%
% of All Funds
1.69%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
19
Increased
27
Reduced
12
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BI
BVF Inc
California
+$7.26M
2
EC
EcoR1 Capital
California
+$4.99M
3
BlackRock
BlackRock
New York
+$4.05M
4
N
Nuveen
North Carolina
+$1.34M
5
Morgan Stanley
Morgan Stanley
New York
+$888K

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$16.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$696K
3
AG
Artal Group
Luxembourg
-$300K
4
TI
Trexquant Investment
Connecticut
-$204K
5
Wells Fargo
Wells Fargo
California
-$134K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
Alphabet Inc
California
$40.1M – – –
PS
2
Peter Svennilson
$28.1M – – –
BI
3
BVF Inc
California
$28.1M +$7.26M +725,000 +26%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$21.1M -$16.1M -1,607,497 -38%
BlackRock
5
BlackRock
New York
$17.8M +$4.05M +404,432 +22%
EC
6
EcoR1 Capital
California
$11.8M +$4.99M +498,059 +50%
FCMI
7
Foresite Capital Management III
California
$10.9M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$8.69M -$696K -69,525 -6%
State Street
9
State Street
Massachusetts
$4.86M +$698K +69,738 +13%
Janus Henderson Group
10
Janus Henderson Group
United Kingdom
$4.04M +$6.82K +681 +0.1%
JP Morgan Chase
11
JP Morgan Chase
New York
$3.98M +$267K +26,709 +5%
HA
12
HHLR Advisors
Cayman Islands
$3.38M – – –
HIM
13
Hillhouse Investment Management
Cayman Islands
$2.72M – – –
ACM
14
Aisling Capital Management
New York
$2.65M – – –
Northern Trust
15
Northern Trust
Illinois
$2.64M +$187K +18,696 +6%
AG
16
Artal Group
Luxembourg
$2.15M -$300K -30,000 -10%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.83M +$274K +27,360 +13%
PIM
18
Platinum Investment Management
Australia
$1.16M – – –
N
19
Nuveen
North Carolina
$1.06M +$1.34M +133,493 New
BBA
20
Baker Bros. Advisors
New York
$966K – – –
Bank of New York Mellon
21
Bank of New York Mellon
New York
$930K +$99.9K +9,980 +9%
Morgan Stanley
22
Morgan Stanley
New York
$785K +$888K +88,716 +879%
Charles Schwab
23
Charles Schwab
California
$773K -$16.1K -1,609 -2%
Goldman Sachs
24
Goldman Sachs
New York
$737K +$486K +48,563 +110%
Millennium Management
25
Millennium Management
New York
$618K +$778K +77,736 New
1
2 3 4

RCUS Hedge Fund Activity: Q2 2019 in Review

78 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2019, worth a combined $210M — down 35% from $322M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RCUS positions and 3 closed out — a net gain of 16 holders — while 27 added to existing stakes and 12 trimmed.

The largest buyer was BVF Inc, adding an estimated $7.26M. The largest seller was Wellington Management Group, cutting an estimated $16.1M.

  • 78 institutional investors held Arcus Biosciences (RCUS) as of Q2 2019, up from 64 in Q1 2019.
  • Funds reported $210M of Arcus Biosciences stock for Q2 2019, down 35% quarter-over-quarter.
  • 19 funds opened new Arcus Biosciences positions in Q2 2019 and 3 closed out, a net change of +16 holders.
  • The largest Arcus Biosciences buyer in Q2 2019 was BVF Inc, an estimated $7.26M added.
  • The largest Arcus Biosciences seller in Q2 2019 was Wellington Management Group, an estimated $16.1M sold.

Based on aggregated 13F filings for Q2 2019.